Develops gene therapies for rare genetic diseases and retinal disorders, aiming to provide transformative treatments for patients with unmet medical needs.
Haleon plc, headquartered in Brentford, United Kingdom, is a leading global player in the consumer healthcare sector. Established in 2021 under the name DRVW 2022 plc before rebranding in February 2022, Haleon specializes in researching, developing, manufacturing, and distributing a diverse array of consumer healthcare products. These products span therapeutic oral health, pain relief, respiratory health, digestive health, and a comprehensive range of vitamins, minerals, and supplements. The company operates across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific, ensuring broad accessibility to its extensive portfolio.
Central to Haleon plc's success are its renowned brands, which include household names such as Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. These brands are trusted worldwide for their efficacy and quality, catering to diverse consumer needs across different demographics and markets. Haleon plc leverages its robust research and development capabilities to continually innovate and enhance its product offerings, ensuring they remain at the forefront of consumer preferences and medical advancements.
With a commitment to improving global health and wellness, Haleon plc combines scientific expertise with a dedication to corporate responsibility. The company adheres to stringent regulatory standards while striving for sustainable practices in its operations. Through strategic expansion and a focus on delivering superior healthcare solutions, Haleon plc continues to strengthen its position as a leader in the competitive consumer healthcare industry.